CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...